WALL ST TRENDS
DATED, PUBLIC, VERIFIABLE EVENTS

Lantheus: A Profitable Radiopharma Company With a Cluster of Dated FDA Catalysts

NASDAQ: LNTH Lantheus Holdings, Inc. | Bedford, MA | Data as of July 2026 — verify before acting

Unlike a speculative single-drug biotech, Lantheus is an established, profitable imaging company (PYLARIFY, DEFINITY) with several near-term, publiclydated FDA decisions and reported takeover interest. The events below are real and on the calendar — that's the entire basis for any "near-term catalyst" framing. **This is our own independent research, not investment advice, and not a recommendation to buy or sell.**

THE DATED CATALYSTS (WHY "NEAR-TERM" IS LITERAL HERE)

Jun 29, 2026
PDUFA decision on LNTH-2501 (Ga-68 edotreotide), a PET imaging kit for neuroendocrine tumors. FDA's prior delay was manufacturing-related — explicitly not a safety/efficacy concern.

Aug 13, 2026
PDUFA decision on MK-6240, a tau-targeted PET imaging agent for Alzheimer's — a larger potential market than LNTH-2501.

Ongoing
Reported takeover interest (Bloomberg, May 2026): Lantheus said to be weighing a possible sale after a Curium offer. May or may not result in a deal.

~$103	~$7B	$1.49–1.51B	$5.50–5.65	$47–109	Profitable
SHARE PRICE	MARKET CAP	FY26 REV GUIDE	FY26 ADJ EPS GUIDE	52-WK RANGE	VS. CASH-BURN BIOTECH

THE BULL CASE

- **Real earnings, not a story.** Profitable with strong free cash flow and multi-billion revenue guidance — downside is cushioned by the existing business.
- **Catalyst stack.** Two dated FDA decisions within ~7 weeks plus M&A optionality; multiple shots rather than one binary.
- **Manufacturing-only delay.** The LNTH-2501 extension was tied to manufacturing information, not clinical data — a relatively more favorable reason for a delay.
- **Sell-side support.** Several firms raised targets to ~$115 (e.g., Mizuho, Truist) in May 2026.

THE BEAR CASE

- **Already ran.** Shares climbed ~57% over six months and sit near the 52-week high — a lot may be priced in.
- **Modest catalyst magnitude.** LNTH-2501 is an incremental diagnostic for a company this size, not a transformational approval.
- **Mixed ratings.** Not unanimous — at least one firm (Baptista) issued a Sell in June 2026.
- **Deal risk.** If takeover speculation fades with no deal, the M&A premium in the price can unwind.

HOW TO THINK ABOUT A CATALYST TRADE — READ THIS

FDA decisions are binary, low-visibility events. Stocks often "run up" into a PDUFA date and then **sell the news even on approval**; a Complete Response Letter (rejection) can cause a sharp drop. You do not have an information edge over the market on the outcome. Treat any catalyst position as high-risk, size it accordingly, and never invest money you can't afford to lose. Being "early" to a calendar date is not the same as being early to a price move.

IMPORTANT DISCLOSURES — READ BEFORE ACTING

This is independent research and opinion published under the Wall St Trends. It is NOT investment advice and NOT a recommendation to buy, sell, or hold any security. It was not prepared by a registered investment adviser or dealer and reflects the publisher's own analysis of public information, which may be wrong.

Compensation: Wall St Trends has **not** been compensated by Lantheus or any third party to produce or distribute this note. (Wall St Trends publishes both independent research like this and, separately, paid promotional content; paid pieces carry their own compensation disclosure. This piece is the former.) **Position:** Wall St Trends and/or its principals do not hold a position in LNTH and may buy or sell at any time without notice — including before or around the catalyst dates above, which would be a conflict of interest you should weigh.

Catalyst & timing: PDUFA dates are FDA targets; decisions can land early, on, or after the date, or be delayed again. Prices and analyst targets move quickly, especially on M&A headlines — re-verify the share price, the catalyst dates, and any deal status against primary sources (company press releases, SEC filings, FDA) immediately before acting. Figures here are as of mid-June 2026 and are approximate.

Risk: All equity investing carries risk of loss, including total loss. Biotech/FDA catalyst events are especially volatile. Do your own due diligence and consult a licensed professional.

Sources: Lantheus press releases & Form 8-K filings (SEC EDGAR / GlobeNewswire), incl. Mar 17 & May 7, 2026; FDA PDUFA calendar entries; Bloomberg M&A reporting (via TipRanks, May 22, 2026); analyst actions via TipRanks/CNN; market data via Investing.com (Jun 2026). Market data is approximate and may be stale.